Effect of Intraoperative Magnesium on Remifentanil-induced Postoperative Hyperalgesia After Thyroidectomy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01025245

Enrollment

Registered

2009-12-03

Start date

2009-11-30

Completion date

2010-01-31

Last updated

2010-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperalgesia

Keywords

Remifentanil induced postoperative hyperalgesia

Brief summary

The purpose of this study is to study the effect of intraoperative magnesium on remifentanil-induced postoperative hyperalgesia after thyroidectomy

Interventions

DRUGremifentanil, MgSO4

Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ & Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.

Study design

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients undergoing thyroidectomy, * Age 20-65, * American Society of Anesthesiologists physical status classification I or II.

Exclusion criteria

* History of chronic pain, Regular use of analgesic, antiepileptic or antidepressive drugs, * History of drug & alcohol abuse, * Psychiatric disorder, * Use of opioids within 24hrs, * Renal disease with decreased GFR, * Neuromuscular disease, Severe cardiac disease.

Design outcomes

Primary

Measure	Time frame
Tactile pain thresholds adjacent to the surgical wound assessed by von Frey hair before the induction and at postoperative 24 & 48 hrs	postoperative 48 hrs

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026